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Summary An isolated rat hindlimb perfusion model carrying xenografts of the human melanoma cell line MM96 was used tostudythe effects
of perfusion conditions on melphalan distribution. Krebs-Henseleit buffer and Hartmann's solution containing 4.7% bovine serum albumin
(BSA) or 2.8% dextran 40 were used as perfusates. Melphalan concentrations in perfusate, tumour nodules and normal tissues were
measured using high-performance liquid chromatography (HPLC). Increasing the perfusion flow rates (from 4 to 8 ml min-') resulted in higher
tissue blood flow (determined with 5'Cr-labelled microspheres) and melphalan uptake by tumour and normal tissues. The distribution of
melphalan within tumour nodules and normal tissues was similar for both Krebs-Henseleit buffer and Hartmann's solution; however, tissue
concentrations of melphalan were significantly higher for a perfusate containing 2.8% dextran 40 than for one containing 4.7% BSA. The
melphalan concentration in the tumour was one-third of that found in the skin if the perfusate contained 4.7% BSA. In conclusion, this study
has shown that a high perfusion flow enhances the delivery of melphalan into implanted tumour nodules and normal tissues, and a perfusate
with low melphalan binding (no albumin) is preferred for maximum uptake of drug by the tumour.
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In the management ofmalignant melanoma, isolated limb perfusion
(ILP) with melphalan is an effective method of control for loco-
regional advanced disease and may be an effective adjuvant to
surgery in the treatment ofhigh-risk primary lesions (Kroon, 1988).
To assess the amount of cytostatic drug taken up by the tissues,
pharmacokinetic studies have usually been based on the area under
the concentration - time curve of melphalan in the perfusate
(Benckhuijsen et al, 1985, 1988). Ofmore direct clinical relevance
is the targeting of melphalan within melanoma nodules relative to
normal tissues. Currently, there are limited dataon melphalan distri-
bution in melanoma nodules and within the tissues of the tumour-
bearing limb during ILP (Scott et al, 1990; Klaase et al, 1994a).
Although ILP has been in use for many years to treat recurrent
melanoma restricted to the limbs (Krementz et al, 1987; Scott et al,
1992a; Thompson et al, 1994a) and sarcomas of the extremities
(Englund et al, 1971; Lejeune et al, 1988; Kettelhack et al, 1990),
the optimal perfusion conditions have been ill defined. Currently,
different perfusate compositions are used in the different centres
undertaking ILP: Ringer's lactate solution with packed red cells or
whole blood (Krementz et al, 1987; Scott et al, 1992a); electrolyte
solution with whole blood (Kroon, 1988; Klasse et al, 1994a); or
Hartmann's solution (high chloride content) with packed red cells
(Thompson et al, 1994a) and the inclusion of dextran to maintain
oncotic pressure (Egerton, 1982). We are not aware of any study
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that has compared the effects of variations in perfusate composi-
tion on melphalan distribution within tumour nodules and normal
tissues during ILP.
Perfusion flow rate may affect both the physiology of the limb
and the uptake of melphalan into tumour nodules. An argument
against the use of high perfusion flow rates in ILP is the potential
increased incidence of oedema, localized toxicity and leakage of
melphalan to the systemic circulation with higher morbidity
(Kroon, 1988; Omlor et al, 1990; Klaase et al, 1994b; Vrouenraets
et al, 1995). However, flow rates higher than the physiological
flow have been advocated to provide higheroxygenation (Fontijne
et al, 1984, 1985) or enable optimal tissue temperatures to be
achieved more rapidly (Thompson et al, 1994a). We have found
that high flow rates also lead to an increasedrecruitment ofvessels
and, if the oncotic pressure is inadequate, fluid retention in limbs
(Wu et al, 1993; Cross et al, 1994). Thus, one needs to feel confi-
dent that an increase in flow rate will improve tumour exposure to
the melphalan.
An isolated perfused tumour-bearing rat hindlimb (Wu et al,
1993, 1996) was used to study the extent to which melphalan
targeted the tumour nodules. The aims of the present study were:
(1) to compare melphalan distribution in melanoma nodules within
the tissues in the isolated perfused rat hindlimb using the following
perfusate compositions: (a) Krebs-Henseleit buffer containing
4.7% bovine serum albumin (BSA), (b) Krebs-Henseleit buffer
containing 2.8% dextran 40, (c) Hartmann's solution containing
4.7% BSA and (d) Hartmann's solution containing 2.8% dextran
40; and (2) to compare melphalan uptake into tumour and normal
tissues with perfusion flow rates of 4 and 8 ml min-' by using
Krebs-Henseleit buffer.
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MATERIALS AND METHODS
Nude rats
Male nude rats (Animal Resources Centre, Willetton, WA,
Australia) weighing from 230 to 265 g were fed a standard
commercial diet and water ad libitum in a pathogen-free rat room.
The experimental protocol was approved by the University of
Queensland Animal Experimentation Ethics Committee.
Human melanoma implantation onto model
The origin and general properties ofthe human melanoma cell line
MM96L, established from alymph node metastasis, haspreviously
been described (Parsons et al, 1982; Clark et al, 1994). Cells were
cultured in Roswell Park Memorial Institute Tissue Medium 1640
(Commonwealth Serum Laboratories, Melbourne, Australia),
containing 5% fetal calf serum, 1 mm pyruvate, 0.2 mM nico-
tinamide, 100 U ml-' penicillin, 0.17 mm streptomycin and 3 mM
4-(2-hydroxyethyl)-l-piperazine ethanesulphonic acid. Cultures
were incubated in air/5% carbon dioxide at 370C and were free of
Mycoplasma as determined by the fluorescent Hoechst 33258
staining method (Goss and Parsons, 1977).
Implantation was performed after the rats were anaesthetized
with intraperitoneal ketamine (80 mg kg-') and xylazine (10 mg
kg-'). The MM96L cells (2 x 106) were injected subcutaneously at
four positions on the right hindlimb (Wu et al, 1996). Perfusion
was carried out when the deposits in the hindlimb reached 5-6 mm
in size, usually 4-6 weeks after implantation.
Isolated perfused rat hindlimb
Details ofthe single-pass rat hindlimb perfusion system have been
described previously (Wu et al, 1993). Briefly, tumour-bearing
nude rats were anaesthetized, the abdomen opened and the right
femoral artery cannulated (PE 50, Clay Adams, USA) via the
dorsal aorta. A second cannula (PE 205, Clay Adams, USA) was
placed in the dorsal vena cava, and the hindlimb perfused in a
Humidicrib with oxygenated (95% oxygen/5% carbon dioxide)
Krebs-Henseleit buffer or Hartmann's solution (pH 7.4, 37°C)
containing 4.7% BSA (Fraction V, Sigma Chemical, Australia)
or2.8% dextran 40 (SigmaChemical) to maintain the oncotic pres-
sure in the perfused rat hindlimb (Cross et al, 1994). The perfused
hindlimb viability was monitored by the difference of inflow and
outflow concentrations of potassium (K+), creatine kinase (CK)
and lactate dehydrogenase (LDH) as markerofcell damage (Wu et
al, 1993). A perfusion flow rate of4 or 8 ml min-' was used with a
60-min melphalan perfusion time in each rat hindlimb.
Perfusate sampling protocols
Melphalan was donated by Wellcome (Sydney, Australia). The
melphalan powder was dissolved in HPLC-grade methanol to give
a stock solution of 1 mg ml-', which was further diluted in
perfusate (15 jg ml-') before perfusion of the rat hindlimb (final
methanol concentration, 1.5%). Inflow and outflow samples were
taken at times of0, 4, 8, 16, 20, 30, 40, 50 and 60 min. Following
the perfusion, the rats were sacrificed, and tissue samples (skin,
fat, superficial muscle, deep muscle and tumour) were taken for
melphalan analysis.
Melphalan analysis by HPLC
Our technique of HPLC assay for melphalan concentrations in
perfusate and tissues has been reported previously (Wu et al,
1995a). Briefly, a model LC-6AD pump with a SCL-6B system
controller, a SIL-6B autoinjection and a model RF-551 program-
mable spectrofluorimeter were used for detection (Shimadzu,
Kyoto, Japan). Analysis was performed using an Alltima phenyl
column,5 jm, 250 mm x4.6 mm ID (Alltech, Deerfield, IL, USA).
Detector output was processed and manipulated with a Delta chro-
matography data system (Digital Solutions, Brisbane, Australia)
operating on a 486SX personal computer. The mobile phase
consisted of methanol-water-glacial acetic acid [25:75:2 (v/v),
pH 2.7], with l-octanesulphonic acid added at a concentration of
50 mg 100 ml-'. The flow rate was 2 ml per min and the injection
volume was 20g1. The detector was programmed to 265 nm excita-
tion and 360 nm emission formelphalan and 265 nm excitation and
575 nm emission for the internal standard (dansyl-arginine).
Perfusate samples of 100 pl were vortexed with 200 p1 of
methanol containing dansyl-arginine (38 jg ml-') as internal stan-
dard at 4°C for 30 s and then clarified by centrifugation at
10 000 g for 15 min. An aliquot (100 pl) of the supernatant was
removed for analysis and 20 g1 injected onto the HPLC system.
Tissue samples (skin, fat, superficial muscle, deep muscle and
tumour, approx. 100 mg) were minced using scissors and
suspended in 200 pl of methanol containing dansyl-arginine. The
mixture was sonicated, on ice, for 1 min using an ultrasonic
microtip and centrifuged at 10 000 g for 15 min. The supernatant
was then removed and 20 pl injected on to the HPLC system. The
sensitivity ofthis assay for melphalan is 1.4 and 7.2 ng on column
in perfusate and tissues respectively (Wu et al, 1995a).
Tissue blood flow measured by 51Cr-labelled
microspheres
Microspheres (10 jim diameter) are trapped as they enterthe nutri-
tive capillaries (average capillary diameter 1-8 jim) of the
vascular beds they perfuse and have therefore been extensively
used to quantify regional capillary blood flow (Hales, 1974; Hales
et al, 1979). A known amount (1.5 x 105 c.p.m.) of 10-jm 5'Cr-
labelled microspheres (NEN-Trac, New England Nuclear,
Wilmington, DE, USA) was prepared as an injection mixture with
200 jil of saline and 0.05% Tween 20 (Cross et al, 1994; Wu et al,
1995b). The actual dose administered (D) was calculated by the
differences in the counts per minute (c.p.m.) of the injection
mixture (Di) and the c.p.m. of microspheres remaining in the
catheter and syringe after injection (Dcathi). The microspheres were
injected as a bolus into the arterial catheters ofperfused hindlimbs
after a 57-min perfusion by Krebs-Henseleit buffer under various
perfusion conditions: perfusate containing (a) 4.7% BSA, (b) 2.8%
dextran 40 without melphalan perfusion at a flow rate of 4 ml
min; perfusate containing (c) 4.7% BSA, (d) 2.8% dextran 40
with melphalan perfusion at a flow rate of4 ml min-'; (e) perfusate
containing 4.7% BSA with melphalan at a flow rate of8 ml min-'.
Outflow samples werecollected at 2- and 10-s intervals for3 min
and the perfusion was then stopped. The hindlimb tissues were
completely dissected into preweighed Eppendorf tubes, and the
microspheres in the tissues and catheterweredetermined in aCobra
II gamma counter (Packard, Meriden, CT, USA). The tissue flow
rate, QT (ml min-' g- oftissue), in each tissue was determined from
the following relationship (Heymann et al, 1977; Wu et al, 1995b):
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Figure 1 (A) Tissue blood flows measured by 51Cr-labelled microspheres and (B) tissue melphalan concentration after melphalan (15 gg ml-') perfusion for
60 min with Krebs-Henseleit buffer in various perfusion conditions: perfusate containing 4.7% BSA (E) or 2.8% dextran 40 (Z) at perfusion flow rate of 4 ml
min-'; perfusate containing 4.7% BSA (E) at perfusion flow rate of 8 ml min-1. Melphalan concentration profiles in inflow (C) and outflow (D) after melphalan
(15 ig ml-') perfusion for 60 min with Krebs-Henseleit buffer in various perfusion conditions: perfusate containing 4.7% BSA (0) or 2.8% dextran 40 (U) at flow
rate of 4 ml min-'; perfusate containing 4.7% BSA (A) at perfusion flow rate of 8 ml min-' (mean ± s.d., n = 3)
Table 1 Comparison of tissue perfusion flow rates (ml min-, g- of tissue) before and after melphalan perfusion with perfusate containing both
4.7% BSA or 2.8% dextran 40 at perfusion flow rate of 4 ml min-' in the isolated perfused tumour-bearing rat hindlimb (mean ± s.d., n =3)
Tissues Perfusate containing 4.7% BSA Perfusate containing 2.8% dextran 40
No melphalan With melphalan No melphalan With melphalan
Skin 0.078 ± 0.034 0.103 ± 0.010 0.108 ± 0.047 0.098 ± 0.010
Fat 0.176 ± 0.013 0.114 ± 0.008 0.142 ± 0.004 0.167 ± 0.018
S muscle 0.109 ± 0.030 0.144 ± 0.026 0.076 ± 0.002 0.096 ± 0.005
D muscle 0.131 ± 0.056 0.156 ± 0.007 0.177± 0.079 0.180± 0.015
Tumour 0.020 ± 0.007 0.023 ± 0.004 0.038 ± 0.011 0.050 ± 0.034
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Figure 2 Comparison of melphalan tissue concentrations after melphalan (15 jg ml-') perfusion for 60 min with Krebs-Henseleit buffer (closed symbol) or
Hartmann's solution (open symbol) containing (A) 4.7% BSA or (B) 2.8% dextran 40 in the perfusate. Melphalan concentration profiles for Hartmann's solution
(@) or Krebs-Henseleit buffer (-) perfusates containing 2.8% dextran in inflow (C) and oufflow (E), or melphalan concentration profile for perfusate containing
4.7% BSA in inflow (D) and outflow (F) (mean ± s.d., n = 3)
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where CT is the c.p.m. of microspheres per gram of the tissue and
Q is the perfusion flow rate (ml min-').
Data analysis
The rate constant (Kh) for melphalan hydrolysis in the inflowing
perfusate was calculated from a semilogarithmic plot of concentra-
tion vs time. The concentration of melphalan in each tissue was
expressed as gg g-' oftissue. The area under the outflow concentra-
tion curve(AUC_,50) was calculated using the lineartrapezoidal rule.
Values are reported as mean ± s.d. and analysis of variance
(ANOVA) with the Tukey test was applied. Statistical significance
was based on P < 0.05.
RESULTS
Viability of the limb preparation
No significant release of various makers (CK, LDH or K+) for
tissue damage were observed in any of the experiments. The loss
ofpotassium over a 120-min perfusion period was less than 2-3%
ofthe total intracellular potassium (4-6 gmol g-1 ofleg weight).
Determination of tissue perfusion flow rate by
microspheres
The mean perfusion pressures were 29.35 ± 2.43 and 41.56±
4.91 mmHg at flow rates of 4 and 8 ml min-', respectively, when
using the microspheres; 62.94 ± 8.12% of microsphere injectate
was injected into the perfused hindlimbs. The recovery of micro-
spheres from the outflow sample collected during the 3-min period
was 0.72 ± 0.29% and 3.17 ± 2.50% for perfusion flow rates of 4
and 8 ml min-', respectively, confirming that most of the micro-
spheres were trapped within microcirculation, but this also
demonstrates that there was probably flow through arteriovenous
anastomoses at the higher perfusion flow rate. The individual
tissue blood flow in the hindlimb, as determined by microsphere
injection, for BSA-containing perfusate and flow rates of 4 and
8 ml min-' together with dextran-containing perfusate at a flow of
4 ml min-' are shown in Figure lA. As expected, the individual
tissue blood flows were significantly greater at 8 ml min-' than at
Table 2 The pharmacokinetics of melphalan in isolated perfused tumour-
bearing rat hindlimb with various perfusate conditions (mean ± s.d., n = 3)
Perfusate conditions Flow Kha Peak time AUCOGW
(ml min-') (min-1) (min) (gg ml-' min-')
Krebs-Henseleit with 4 0.111 ± 0.020 30 603.21 ± 48.46
4.7% BSA
Krebs-Henseleit with 4 0.131 ± 0.002 4 538.38 ± 7.76b
2.8% dextran
Krebs-Henseleit with 8 0.120 ± 0.011 8 597.06 ± 47.49
4.7% BSA
Hartmann solution 4 0.091 ± 0.006 30 624.09 ± 42.49
with 4.7% BSA
Hartmann solution 4 0.091 ± 0.018 4 601.39 ± 13.35
with 2.8% dextran
aMelphalan hydrolysis in inflow perfusate. bp< 0.05.
4 ml min-' (P < 0.05). However, the increase in individual tissue
flow rate was less than the twofold change expected. No signifi-
cant difference in tissue blood flow was found for the perfusates
containing 4.7% BSA and 2.8% dextran 40 at aperfusion flow rate
of 4 ml min-'. The tumour blood flow was one-third of the flow
measured in skin and fat; muscle blood flow was generally higher
than all the other tissues (Figure IA). There was no significant
difference (P > 0.05) between tissue blood flows obtained before
and after melphalan administration in perfusate containing either
4.7% BSA or 2.8% dextran 40 (Table 1).
Uptake of melphalan by tissue
The melphalan concentrations in the tissues for Krebs-Henseleit
buffercontaining either4.7% BSA or 2.8% dextran 40 atperfusion
flow rates of4 ml min-' or 4.7% BSA at a flow rate of 8 ml min-',
are shown in Figure lB. The melphalan concentration in the
tissues was higher with the perfusate based on dextran than with
the perfusate based on albumin (P < 0.001). Melphalan concentra-
tion in the tumour was three times higher when dextran was used.
Increasing the perfusion flow rate in the albumin buffer enhanced
the melphalan concentration in the perfused tissues (P < 0.05)
(Figure 1B). The melphalan concentrations in all of the tissues
including the tumour were not significantly different between the
perfusate based on Krebs-Henseleit buffer and Hartmann's solu-
tion which contain either 4.7% BSA (Figure 2A) or 2.8% dextran
(Figure 2B).
Pharmacokinetics of melphalan
The perfusate inflow (Figure IC) and outflow (Figure ID) profiles
ofmelphalan in the perfused hindlimb with buffercontaining BSA
or dextran at a flow rate of4 and 8 ml min-' showed no significant
differences between the different perfusion conditions. The time to
peak melphalan concentration in outflow samples at the high flow
rate was significantly shorter than at the low flow rate (Table 2).
Figure 2 shows a comparison of the melphalan concentrations in
inflow and outflow perfusate with Hartmann's solution and
Krebs-Henseleit buffer containing dextran 40 (Figure 2C and E)
and 4.7% BSA (Figure 2D and F). Melphalan hydrolysis (Kh) in
the inflow perfusate with various perfusion conditions had an
apparent monoexponential decline. The Kh of melphalan in
Hartmann's solution was smaller than that in Krebs-Henseleit
buffer (Table 2), and the AUC060 for melphalan in perfusates
containing 2.8% dextran 40 was significantly smaller than in
perfusate containing 4.7% BSA (Table 2).
DISCUSSION
The nude rat hindlimb implanted with human melanoma xenograft
has been designed to mimic some aspects of human isolated limb
perfusion with melphalan. The implanted melanoma is from a cell
line developed from a lymph node secondary and was injected into
the subcutaneous tissue. Given that melanoma recurrence treated
by ILP is 'in transit' within subdermal lymphatics, the rat model
offers a similar situation to that seen in humans.
The neovascularization and other potential artifacts ofimplanta-
tion may cause some difference in comparison with humans.
However, the model still offers the ability to access all the normal
tissue within a limb along with the tumour following a limb perfus-
ion with a cytotoxic agent. Thus, the pharmacokinetics of drug
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delivery may be examined more closely. We have used this isolated
perfused tumour-bearing rat hindlimb model to study the
melphalan distribution in the limb tissues and implanted melanoma
tumours with different perfusate flow rates and composition.
Flow and melphalan concentration
It has been stated that it is desirable to know the proportions of
administered melphalan taken up by the tissues and the tumours in
a leg during ILP (Scott et al, 1992b). We found that the perfusion
flow rate increased proportionally more (1.5-fold) in the skin, fat
and muscle than in the tumour (1.2-fold) ofthe melanoma-bearing
rat hindlimb, when the perfusion rate is doubled from 4 to 8 ml
min-'. The tissue flow rates in skin, fat and muscle were similar to
those previously obtained in this model (Cross et al, 1994, Wu et
al, 1995a, 1996). The flow rate in the tumouris almost one-third of
the flow in skin and fat. The implication is that there was incom-
plete vascularization ofthe subcutaneous tumournodule; however,
this does not detract from the ability to see a change in concentra-
tion ofthe drug related to a change in perfusion condition.
The rat hindlimb consists of60% muscle, 19% skin and 3% fat,
indicating that the majority ofthe blood flow is likely to be within
the muscles (Wu et al, 1995a). High flow rates lead to an increased
recruitment of previously poorly perfused vessels and, if the
oncotic pressure is inadequate, fluid retention will occur in the
limb (Wu et al, 1993; Cross et al, 1994). In ILP, the use of high
perfusion flow rates was advocated to improve oxygenation
(Fontijne et al, 1984, 1985) and to achieve optimal tissue tempera-
tures more rapidly (Thompson et al, 1994b). However, high flow
rates in human ILP could lead to a higher incidence of oedema,
localized toxicity and a higher leakage of melphalan into the
systemic circulation (Kroon, 1988; Omlor et al, 1990; Klaase et al,
1994b). Troublesome problems, such as oedema, blistering and
subsequent desquamation ofthe fingers and the palm orthe sole of
foot (for lower limb), with the loss of finger or toe nails, can be
prevented by firmly wrapping the hand or foot with an Esmarch-
type rubber bandage immediately before drug injection into the
perfusion circuit (Thompson et al, 1994a). In addition, increased
toxicity as induced by enzymes or potassium release from
perfused limb was not observed in this study when the perfusion
flow rate increased.
Perfusate compositions and tissue concentrations of
melphalan
Scott et al (1990) found a similar mean melphalan concentration in
tumour and healthy skin during LLP using Ringer's lactate solution
with packed red cells. Klaase et al (1994a) reported preferential
uptake of melphalan into tumour tissue during ILP using elec-
trolyte solution with whole blood. Similar concentrations of
melphalan in the skin and the tumour were found in our study
using perfusates based on dextran 40, but not with albumin-based
perfusate in which the concentration of melphalan in the tumour
was about 30% of that found in the skin and fat. The differences
in tumour nodule and normal tissue melphalan concentration
ratio with dextran- and albumin-based perfusate probably occurs
because of the different binding capacities of the perfusates. The
unbound fraction ofmelphalan was 0.87 ± 0.1 for 2.8% dextran 40
and 0.52 ± 0.04 for4.7% BSA (albumin) (Wu et al, 1995a). On the
other hand, albumin can also impair the paracellular transport of
drug ions in the capillary circulation (Morgan and Xu, 1994).
Therefore, aperfusate with low melphalan binding (no albumin) is
preferred for maximum uptake ofdrug by the tumour in ILP.
Chang et al (1979) reported that the presence of chloride in
aqueous solution slows down melphalan hydrolysis. Hartmann's
solution (55 mm chloride) contains a relatively high chloride
content and has been used by two groups to treat recurrent
melanoma in ILP (Scott et al, 1987; Thompson et al, 1994a). Other
perfusates that have been used in ILP also contain chloride, e.g.
Ringer's lactate solution (18 mM) (Krementz et al, 1987), elec-
trolyte solution (22 mM) (Kroon, 1988) and Krebs-Henseleit
buffer (15 mM) (Wu et al, 1993). In this study, we have shown that
melphalan hydrolysis occurs marginally slower in Hartmann's
solution than in Krebs-Henseleit buffer. Hartmann's solution is
readily available, has been used in human ILP for many years with
good success rates for melanoma management (Scott et al, 1987;
Thompson et al, 1994a) and has no melphalan-binding com-
ponent. Based on these results, the continued use of Hartmann's
solution in ILP seems appropriate.
Overall, the results from this study suggest that high flow rate
and protein-free perfusate may enhance the effectiveness of ILP
with melphalan for melanoma treatment.
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